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Renal dysfunction is well-known as a potent predictor of the
clinical course in heart failure (HF) patients. Large epide-
miological studies, such as ADHERE (Acute Decompen-
sated Heart Failure National Registry), OPTIMIZE-HF
(Organized Program To Initiate life-saving treatMent in
hospitaliZEd patients with Heart Failure), and EURO-HF
(European Heart Failure), reveal that 30% to 67% of
patients hospitalized for decompensated HF have a glomer-
ular filtration rate (GFR) 60 ml/min/1.73 m2 (1–3). The
main pathophysiological mechanism of impaired renal func-
tion in HF patients is activation of the neurohumoral axis;
specifically, the sympathetic nervous system, renin-
angiotensin-aldosterone system, and arginine vasopressin
are stimulated to compensate for the decreased cardiac
output or stroke volume in the HF patients (Fig. 1) (4). The
resultant increase in systemic vascular resistance in HF
includes vasoconstriction of the kidney. The severity of the
renal dysfunction in HF patients correlates with increased
mortality and rehospitalization (5).
See page 1709
Thus, the accurate estimate of GFR in HF patients is
critical. The assessment of GFR by inulin clearance, nuclear
scan, or creatinine clearance, however, is unsuitable for clinical
practice. Therefore, several formulas to estimate kidney func-
tion have been proposed. These include the Cockroft-Gault
(C-G) formula to estimate creatinine clearance and the Mod-
ification of Diet in Renal Disease (MDRD) and Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) for-
mulas to estimate the GFR. The MDRD formula was intro-
duced by the Modification of Diet in Renal Disease Study
Group in 1999 (6) and re-evaluated for use with standardized
serum creatinine values in 2005 (7). It was based on a group of
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prediction formulas for renal function as recommended by the
National Kidney Foundation Kidney Disease Outcomes Qual-
ity Initiative (KDOQI) (8).
Another formula to estimate the GFR recommended by
KDOQI was the C-G formula (9), which was developed to
calculate creatinine clearance. The CKD-EPI formula to
estimate GFR was developed in 2009 (10). It is a more
accurate formula than the MDRD formula for patients with
a GFR 60 ml/min/1.73 m2. The results in CKD patients
ith a GFR 60 ml/min/1.73 m2 are comparable to those
sing the MDRD formula. However, only a small number of
lderly patients, ethnic minorities, and patients with a higher
FR have been evaluated using the CKD-EPI formula.
Despite the importance of renal dysfunction in HF
atients, there is a paucity of results comparing these
ormulas in this population. In this issue of the Journal,
amora et al. (11) compare the prognostic value of the
DRD-4, CKD-EPI, and C-G formulas for mortality in
25 HF patients in an outpatient setting. The HF patients
ere observed over 3 years and were mainly New York
eart Association (NYHA) functional class II/III. The
atients’ characteristics and comorbidities were quite typical
f an outpatient cardiology practice. There were more male
han female patients, and the mean age was 70 years.
schemic cardiomyopathy constituted 56% of the patients,
nd the median left ventricular ejection fraction was 31%.
ore than one half of the patients had been hospitalized
uring the previous year for HF treatment. Arterial hyper-
ension was present in 58% of the patients, and more than
ne third had diabetes mellitus. Seventeen percent of the
atients had anemia, defined as a hemoglobin level 12
/dl. The daily HF treatment included angiotensin-
onverting enzyme inhibitors or angiotensin II receptor
lockers (88.6%), beta-blockers (81%), and loop diuretics
83%), and approximately one third received aldosterone
eceptors antagonists. Thus, the study population was rep-
esentative of an outpatient HF practice.
Renal dysfunction as defined by an estimated GFR
eGFR) 60 ml/min/1.73 m2 occurred in approximately
half of these outpatients with NYHA functional class II/III
symptoms, namely, C-G (58.3%), MDRD-4 (48.4%), and
CKD-EPI (53.4%). All 3 formulas were predictors of
long-term mortality, and the worst prognosis was in HF
patients with an eGFR 30 ml/min/1.73 m2.
The C-G formula was the most accurate for prediction of
HF mortality in this outpatient population. With the C-G
formula, more patients had an eGFR 60 and 30
ml/min/1.73 m2 compared with MDRD and CKD-EPI for-
ulas. The HF patients with an eGFR30 ml/min/1.73 m2, as
delineated by the C-G formula, were older and had a lower
body mass index (BMI) than those classified by the MDRD
or CKD-EPI formula. In this regard, the C-G formula, but
not MDRD or CKD-EPI formula, includes body weight,
which is an important component of BMI (kg body
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hat a decrease in lean body mass correlates with increased
ortality in HF patients (12). In the CHARM (Candesar-
an in Heart Failure: Assessment of Reduction in Mortality
nd Morbidity) study of HF patients, there was an increase
n the risk of all-cause death of 3.3% for every 1-kg/m2
decrease in BMI (12). This finding persisted after adjust-
ments for age and sex. These results in advanced HF may
suggest the presence of cardiac cachexia.
Of interest, the C-G formula also has been shown to be
better than the MDRD formula to predict a high-risk group
in patients with non–ST-segment elevation acute coronary
syndromes (13). Moreover, more patients requiring antico-
agulant dose adjustments were identified by the C-G
formula, particularly among subgroups at high risk of
bleeding. This finding is also consistent with C-G formula
identifying more high-risk patients.
Thus, although in the Zamora et al. (11) study the C-G
formula identified more high-risk patients than either the
MDRD or CKD-EPI formula, all 3 formulas correlated
well with increased mortality. These formulas have the
advantage over serum creatinine concentration alone be-
cause they adjust for sex and age. The blood urea nitrogen
level has been found to be more sensitive in predicting
high-risk HF patients than serum creatinine clearance. This
may be because renal urea reabsorption is enhanced by
arginine vasopressin, which increases with activation of the
Figure 1 Pathophysiology of Low-Output Cardiac Failure
With arterial underfilling secondary to a decrease in cardiac output the neurohumo
vasoconstricted as part of this process. Modified, with permission, from Schrier (4neurohumoral axis in advanced HF patients (14).Reprint requests and correspondence: Dr. Robert W. Schrier,
Department of Medicine, University of Colorado Denver, 12700
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